Arvinas, Inc..
ARVN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Arvinas, Inc. is a biopharmaceutical company focused on improving the lives of patients with debilitating diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company pioneered the development of PROTAC (PROteolysis TArgeting Chim...Show More
Better Health for All
-20
Arvinas is a clinical-stage biotechnology company entirely devoted to improving health outcomes by developing therapies for serious and life-threatening diseases, including various cancers and neurological disorders.
1
Its investigational drugs are designed to deliver exceptional health benefits, with one drug demonstrating statistically significant and clinically meaningful improvement in progression-free survival in a Phase 3 trial for a specific breast cancer population.
2
As a clinical-stage company, it has no revenue from commercialized products, thus no revenue from products with established negative health outcomes. The company is pioneering therapies using its proprietary PROTAC protein degradation platform, representing a novel approach to drug development.
3
Arvinas has an Expanded Access Policy for patients with serious or immediately life-threatening diseases who have exhausted other treatment options, aiming to respond to requests within 3 business days.
4
However, there is no quantitative data on the percentage of revenue or budget allocated to health equity programs. The company's community service efforts include educating over 250 students in financial literacy, careers, and entrepreneurship, and preparing meals for the homeless.
5
Clinical trials are being conducted to determine the safety and effectiveness of investigational treatments, and the company advises patients to consult physicians to determine trial suitability.
6
The VERITAC-2 trial enrolled 624 patients across 26 countries.
7
Fair Money & Economic Opportunity
0
Arvinas, Inc. is a biopharmaceutical company, and its core business does not involve lending, insuring, moving, or storing money for consumers. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment, debt burden ratio, geographic inclusion, and product simplicity, are not applicable. While Arvinas volunteers participated in a Junior Achievement (JA-in-a-Day) program educating over three hundred K-5 students in the Greater New Haven area,
1
this is a community engagement activity and not a financial literacy program offered by a financial services company, making the financial literacy initiatives KPI also not applicable in this context.
Fair Pay & Worker Respect
40
Arvinas's CEO-to-median employee pay ratio for fiscal year 2024 was 44:1.
1
The company offers comprehensive health, dental, and vision insurance to full-time employees in the United States, and also pays a portion of health coverage premiums for employees continuing under COBRA.
2
Employee reviews on Glassdoor indicate a high overall satisfaction, with an average rating of 4.5 out of 5 stars and 89% of employees recommending working at Arvinas to a friend.
3
The company also provides a 401(k) matching program, an Employee Stock Purchase Plan, tuition reimbursement, fitness reimbursement, and paid maternity/paternity leave.
4
Fair Trade & Ethical Sourcing
0
No specific, quantitative evidence was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing for ARVN.US. The articles primarily discuss internal corporate governance, financial performance, clinical trials, and general business conduct, without detailing supplier-specific practices, certifications, audit frequencies, incident reports, traceability, remediation processes, ethical clauses in supplier contracts, materials risk, or supplier diversity spend.
1
Honest & Fair Business
0
Arvinas, Inc. has a comprehensive Code of Business Conduct and Ethics, last updated in September 2024, which is distributed annually to all employees, officers, and directors, who are required to certify they have read and understood it.
1
The company operates a confidential and anonymous concern hotline (1-866-270-3699) for reporting issues including accounting, auditing, internal controls, human resources, retaliation, and violations of law or company policy.
2
The company explicitly states it does not tolerate retaliation against those who make good faith reports.
3
Messages submitted via the hotline are encrypted and delivered to the General Counsel and, for financial concerns, the Chair of the Audit Committee, with a code provided for anonymous follow-up.
4
However, the effectiveness of this program, such as uptake rates or resolution times, is not publicly measured. The company has not had any financial restatements in the past five years.
5
The board of directors has determined that 90% (9 out of 10) of its members are independent.
6
The company's Code of Business Conduct and Ethics prohibits bribes, kickbacks, and other improper payments, and requires compliance with anti-corruption laws like the FCPA and Bribery Act, applying to all subsidiaries worldwide.
7
However, the policy's training frequency and effectiveness metrics are not detailed. While Deloitte & Touche LLP serves as the independent registered public accounting firm and the compensation committee engages Aon as an independent consultant, the overall extent of independent verification of ethical claims and compliance is not broadly disclosed.
8
Kind to Animals
-40
Arvinas conducts animal studies for drug efficacy and pharmacokinetics, including xenograft models in mice and uterotrophic assays in rats.
1
These studies are performed in compliance with Institutional Animal Care and Use Committee (IACUC) approved protocols and NIH Guidelines for the Care and Use of Laboratory Animals.
2
One protocol was approved as Category D, indicating pain and distress were alleviated by analgesics or anesthetics.
3
The company used 4 mice per arm in one xenograft study, 3 mice per group in another, 5 rats per arm in a uterotrophic assay, 3 SCID mice per arm in a PK study, 6 Sprague Dawley rats in another PK study, 33 CD-1 male mice across 4 treatment groups in a GNE-02 PK study, and 6 NU/NU Nude mice per group in a tumor-bearing PK/PD study.
4
The total number of animals used across these specific studies is 60 mice and 11 rats, with additional unspecified numbers for other studies.
No War, No Weapons
0
No specific, concrete evidence was found in the provided articles to assess Arvinas, Inc. against any of the KPIs for the 'No War, No Weapons' ethical value. The articles contained general meeting statistics, information pertaining to Johnson Controls, or Arvinas's Code of Business Conduct and Ethics, none of which provided data points related to arms manufacturing, military contracts, dual-use technology, or peacebuilding initiatives for Arvinas, Inc.
1
,
2
,
3
Planet-Friendly Business
-20
In 2022, the company reported Scope 1 and 2 greenhouse gas emissions of 1,124 metric tons of CO2e.
1
This represents a 15% reduction from 2021.
2
Additionally, Arvinas achieved a waste recycling rate of 68% in 2022.
3
Respect for Cultures & Communities
0
No specific, quantitative evidence was found in the provided articles to assess Arvinas, Inc. against any of the KPIs for Respect for Cultures & Communities. The articles describe general community engagement activities, such as employee volunteer days for education programs, facility enhancements, and environmental cleanups in the Greater New Haven community, but do not provide data on formal partnerships, revenue reinvestment, cultural impact assessments, local employment ratios, or other specific metrics related to cultural respect or community governance.
1
Safe & Smart Tech
0
Arvinas states that, to its knowledge as of August 6, 2021, it has not had any material security breaches or unauthorized uses of its IT Systems and Data.
1
The company also states it is in compliance with applicable laws and regulations related to privacy and security, specifically addressing GDPR and CCPA.
2
Arvinas uses appropriate technical and organizational security measures to protect personal data and has implemented commercially reasonable controls and safeguards for its IT Systems and Data.
3
The company retains personal information only as long as necessary and has established user data control options, including rights for California and EEA/UK residents.
4
The Audit Committee and Board review major risk exposures, including privacy and cybersecurity.
5
The company has implemented backup and disaster recovery technology consistent with industry standards.
6
Zero Waste & Sustainable Products
-20
Arvinas reported a waste recycling rate of 68% in 2022.
1
The company has set a waste recycling target of 75% for 2023.
2